GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, & Establish Advanced Manufacturing Tr...
September 19 2016 - 2:00AM
Business Wire
- GE plans to establish four
prefabricated, off-the-shelf biologics factories for GE customers
in GE BioPark Cork, creating up to 500 jobs
- GE’s factory is between 25 and 50
percent more cost-effective to build than traditional manufacturing
facilities
- GE is also in the process of setting up
a training collaboration with National Institute for Bioprocessing
Research and Training (NIBRT) to develop skills for Ireland’s
biologics sector, training 1,500 professionals per year
Ireland’s Minister for Jobs, Enterprise and Innovation, Mary
Mitchell O’Connor TD, today announced that GE (NYSE:GE) is
to invest €150 million in a new biopharmaceutical manufacturing
campus on Industrial Development Agency (IDA) Ireland’s strategic
site at Loughbeg, Ringaskiddy, Co. Cork. GE BioPark Cork, subject
to contract and planning approvals, will feature Europe’s first
KUBio™, prefabricated, off-the-shelf bio-manufacturing facilities,
owned and run by GE customers, and will serve as focal point for
further investment in next-generation biopharmaceutical
manufacturing in Ireland.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160918005037/en/
Computer simulation of GE Healthcare's
planned BioPark in Cork, Ireland. (Photo: Business Wire)
Building manufacturing capacity
GE BioPark Cork is expected to be home to more than 500 new jobs
when fully operational; 400 with biopharma companies and a further
100 employed directly by GE. The construction phase, subject to
planning approvals, is expected to begin by mid- 2017 and create up
to 800 construction jobs. The project is supported by the
Department of Jobs, Enterprise and Innovation through IDA
Ireland.
Developing bio-manufacturing skills for 1,500
bio-professionals per year
To further develop biopharma manufacturing skills and expertise
in Ireland, GE and the National Institute for Bioprocessing
Research and Training (NIBRT) also announced today their plan to
create a NIBRT-GE Single-use Centre of Excellence at NIBRT’s Dublin
facility. NIBRT expects to train up to 1,500 bioprocessing
professionals annually on next-generation biologic manufacturing
technologies. These exceptional technologies for biopharma
manufacturing will be used in GE BioPark Cork’s manufacturing
facilities.
GE BioPark Cork will be a GE-managed campus including four
fully-equipped KUBio factories owned by independent biopharma
companies manufacturing proprietary medicines, with GE running
centralised shared utilities and site services.
Patient demand for innovative medicines is driving rapid global
growth of the biopharmaceutical industry, resulting in significant
need for more production capacity. GE’s KUBio enables
pharmaceutical companies to quickly deploy new biologics
manufacturing capacity and bring medicines to market faster. KUBios
increase manufacturing flexibility and are between 25 and 50
percent more cost-effective to build than comparable traditional
facilities. Carbon dioxide emissions can be reduced by 75 percent
and water and energy use by approximately 80 percent. Build time
can be shortened to 18 months from the usual 3 years.
Minister Mitchell O’Connor said: "The Biopharma industry
makes a huge contribution to the Irish economy in terms of jobs and
manufacturing exports, and is one of the fastest growing sectors. I
am delighted that GE is making a significant investment in Cork.
This is a further testament to our talented workforce. All
investment and jobs created has a positive knock on effect on the
wider region. Over 28,000 people currently work in biopharma and
6,000 of those work in biologics. This subsector is expected to
double in the coming years and will provide both a challenge and an
opportunity for the industry and training providers to collaborate
on promoting the range of career opportunities available. I welcome
GE's commitment to Ireland and wish them every success in the
future."
Kieran Murphy, CEO, GE Healthcare Life Sciences, said:
“Pharma companies world-wide are racing to respond to patient needs
with new life-changing biological medicines and GE is investing in
technology and service solutions, as well as industry skills and
expertise, to enable them to make and get their products to market
more quickly. We are delighted to be investing once again in
Ireland, where we have ourselves a long history of manufacturing
our own medical imaging products.”
Martin Shanahan, CEO, IDA Ireland, said: “The choice of
Ireland for this strategically important investment by GE is a
significant win. The biopharmaceutical manufacturing campus will
greatly assist IDA Ireland win additional bio-manufacturing
investments by acting as a catalyst to attract new innovator drug
companies and to transition and grow existing operations.”
“Ireland has won more than €10bn in the past 10 years in biotech
investment, building on a long history in pharmaceutical
manufacturing and is now one of the world's top locations for
biopharma, which creates significant secondary employment in
construction and other services.”
Dominic Carolan, CEO, NIBRT, said: “NIBRT is delighted to
partner with GE on the next generation of bioprocessing equipment,
which will accelerate the introduction of these new technologies to
the biopharmaceutical manufacturing industry, helping to reduce
manufacturing costs and increase the access to these valuable
therapies.”
About GE Healthcare
GE Healthcare provides transformational medical technologies and
services to meet the demand for increased access, enhanced quality
and more affordable healthcare around the world. GE (NYSE: GE)
works on things that matter - great people and technologies taking
on tough challenges. From medical imaging, software & IT,
patient monitoring and diagnostics to drug discovery,
biopharmaceutical manufacturing technologies and performance
improvement solutions, GE Healthcare helps medical professionals
deliver great healthcare to their patients. For more information
about GE Healthcare, visit our website at
http://www.gehealthcare.com
About IDA Ireland
Ireland's inward investment promotion agency IDA Ireland is a
non-commercial, semi-state body promoting Foreign Direct Investment
into Ireland through a wide range of services. We partner with
potential and existing investors to help them establish or expand
their operations in Ireland. www.idaireland.com
About NIBRT
The National Institute for Bioprocessing Research and Training
(NIBRT) is a global centre of excellence for training and research
in biopharmaceutical manufacturing. NIBRT is located in a world
class facility in Dublin, Ireland.
NIBRT's mission is to support the growth and development of all
aspects of the biopharmaceutical industry by becoming a global
leader in biopharmaceutical manufacturing research, education and
training. For further information, please visit www.nibrt.ie
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160918005037/en/
GE HealthcareSaara Nordenstr�m, Communications, +46 7386
81286saara.nordenstrom@ge.comorIDA IrelandKevin Sammon, Media
Relations Manager, +353 8 7618
8564Kevin.Sammon@ida.ieorNIBRTKillian O’Driscoll, +353 1 215
8107killian.odriscoll@nibrt.ie
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Aug 2024 to Sep 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Sep 2023 to Sep 2024